Lakeshore Biopharma shares rise 4.49% premarket after receiving a preliminary acquisition proposal from Oceanpine Capital.

Lakeshore Biopharma Co., Ltd rose 4.49% in premarket trading, following the announcement that its board of directors has received a preliminary non-binding proposal letter from Oceanpine Capital to acquire all of the outstanding ordinary shares of the Company that are not currently owned. This news event is positive for the stock as it indicates a potential acquisition, which could lead to increased shareholder value.